Fennec Pharmaceuticals
FENC
90 hedge funds and large institutions have $99.6M invested in Fennec Pharmaceuticals in 2026 Q1 according to their latest regulatory filings, with 16 funds opening new positions, 38 increasing their positions, 18 reducing their positions, and 20 closing their positions.
111% more repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 18
1.65% more ownership
Funds ownership: 45.5% → 47.15% (+1.7%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
6% less funds holding
Funds holding: 96 → 90 (-6)
17% less capital invested
Capital invested by funds: $120M → $99.6M (-$20M)
20% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 20
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
+$3.09M |
| 2 |
RA
Rosalind Advisors
Toronto,
Ontario, Canada
|
+$2.28M |
| 3 |
BlackRock
New York
|
+$1.03M |
| 4 |
PCM
Potomac Capital Management
New York
|
+$998K |
| 5 |
CC
Cornerstone Capital
Palo Alto,
California
|
+$811K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACA
Apis Capital Advisors
New York
|
-$1.57M |
| 2 |
Marshall Wace
London,
United Kingdom
|
-$983K |
| 3 |
SCM
Solas Capital Management
Darien,
Connecticut
|
-$606K |
| 4 |
GJL
Gendell Jeffrey L
|
-$436K |
| 5 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$385K |
FENC Hedge Fund Activity: Q1 2026 in Review
90 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Fennec Pharmaceuticals (FENC) for Q1 2026, worth a combined $99.6M — down 17% from $120M a quarter earlier.
Sellers outnumbered buyers: 20 funds closed out of FENC and 16 opened new positions — a net loss of 4 holders — while 18 trimmed existing stakes and 38 added.
The largest buyer was AIGH Capital Management, adding an estimated $3.09M. The largest seller was Apis Capital Advisors, exiting entirely with an estimated $1.57M sold.
- 90 institutional investors held Fennec Pharmaceuticals (FENC) as of Q1 2026, down from 96 in Q4 2025.
- Funds reported $99.6M of Fennec Pharmaceuticals stock for Q1 2026, down 17% quarter-over-quarter.
- 16 funds opened new Fennec Pharmaceuticals positions in Q1 2026 and 20 closed out, a net change of -4 holders.
- The largest Fennec Pharmaceuticals buyer in Q1 2026 was AIGH Capital Management, an estimated $3.09M added.
- The largest Fennec Pharmaceuticals seller in Q1 2026 was Apis Capital Advisors, an estimated $1.57M sold.
Based on aggregated 13F filings for Q1 2026.